Wang Zheng, Wu Xiaonan, Han Xiaohong, Cheng Gang, Mu Xinlin, Zhang Yuhui, Cui Di, Liu Chang, Liu Dongge, Shi Yuankai
Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
Chin J Cancer Res. 2016 Dec;28(6):606-616. doi: 10.21147/j.issn.1000-9604.2016.06.07.
The relationship between anaplastic lymphoma kinase () expression in malignant pleural effusion (MPE) samples detected only by Ventana immunohistochemistry (IHC) ALK (D5F3) and the efficacy of -tyrosine kinase inhibitor therapy is uncertain.
Ventana anti-ALK (D5F3) rabbit monoclonal primary antibody testing was performed on 313 cell blocks of MPE samples from Chinese patients with advanced lung adenocarcinoma, and fluorescence hybridization (FISH) was used to verify the gene status in Ventana IHC ALK (D5F3)-positive samples. The follow-up clinical data on patients who received crizotinib treatment were recorded.
Of the 313 MPE samples, 27 (8.6%) were confirmed as expression-positive, and the Ventana IHC ALK (D5F3)-positive rate was 17.3% (27/156) in wild-type epidermal growth factor receptor () MPE samples. Twenty-three of the 27 IHC ALK (D5F3)-positive samples were positive by FISH. Of the 11 Ventana IHC ALK (D5F3)-positive patients who received crizotinib therapy, 2 patients had complete response (CR), 5 had partial response (PR) and 3 had stable disease (SD).
The gene expression status detected by the Ventana IHC ALK (D5F3) platform in MPE samples may predict tumor responsiveness to crizotinib in Chinese patients with advanced lung adenocarcinoma.
仅通过Ventana免疫组织化学（IHC）ALK（D5F3）检测的恶性胸腔积液（MPE）样本中间变性淋巴瘤激酶（ALK）表达与ALK-酪氨酸激酶抑制剂治疗疗效之间的关系尚不确定。
对313例中国晚期肺腺癌患者的MPE样本细胞块进行Ventana抗ALK（D5F3）兔单克隆一抗检测，并采用荧光原位杂交（FISH）验证Ventana IHC ALK（D5F3）阳性样本中的ALK基因状态。记录接受克唑替尼治疗患者的后续临床数据。
在313例MPE样本中，27例（8.6%）被确认为ALK表达阳性，野生型表皮生长因子受体（EGFR）MPE样本中Ventana IHC ALK（D5F3）阳性率为17.3%（27/156）。27例IHC ALK（D5F3）阳性样本中有23例FISH检测呈阳性。在11例接受克唑替尼治疗的Ventana IHC ALK（D5F3）阳性患者中，2例完全缓解（CR），5例部分缓解（PR），3例疾病稳定（SD）。
Ventana IHC ALK（D5F3）平台检测的MPE样本中ALK基因表达状态可能预测中国晚期肺腺癌患者对克唑替尼的肿瘤反应性。
